Growth Metrics

Innoviva (INVA) Net Margin (2011 - 2026)

Innoviva posted quarterly Net Margin of 190.38% for Q1 2026, up 24295.0% year-on-year from N/an in Q1 2025, and up 114.94% on a QoQ basis from 1274.01% in Q4 2025.

Innoviva (INVA) has 16 years of Net Margin data on file, last reported at 190.38% in Q1 2026.

  • For the quarter ending Q1 2026, Net Margin rose 24295.0% year-over-year to 190.38%; the trailing twelve-month figure through Mar 2026 stood at 106.25% (up 13869.0% YoY), and the FY2025 full-year result was 65.97%, up 5945.0% from the prior year.
  • Net Margin for Q1 2026 stood at 190.38%, up from 1274.01% in the prior quarter.
  • Across five years, Net Margin topped out at 20424.85% in Q3 2022 and bottomed at 1274.01% in Q4 2025.
  • The 5-year median for Net Margin is 63.51% (2025), against an average of 1580.9%.
  • The widest annual swing landed in 2022, when Net Margin soared 2035083 bps; it then sank 2030286 bps in 2023.
  • A 5-year view of Net Margin shows it stood at 982.68% in 2022, then soared by 56 bps to 430.5% in 2023, then sank by 98 bps to 853.36% in 2024, then plunged by 49 bps to 1274.01% in 2025, then jumped by 115 bps to 190.38% in 2026.
  • The last three Net Margin figures came in at 190.38% (Q1 2026), 1274.01% (Q4 2025), and 83.41% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.82%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 34.53%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 20.17%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 17.65%
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn 190.38%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 190.38%
Dec 31, 2025 -1,274.01%
Sep 30, 2025 83.41%
Jun 30, 2025 63.51%
Mar 31, 2025 -52.56%
Dec 31, 2024 -853.36%
Sep 30, 2024 1.36%
Jun 30, 2024 -34.72%
Mar 31, 2024 3,780.95%
Dec 31, 2023 -430.50%
Sep 30, 2023 121.99%
Jun 30, 2023 130.61%
Mar 31, 2023 4,380.03%
Dec 31, 2022 -982.68%
Sep 30, 2022 20,424.85%
Jun 30, 2022 49.87%
Mar 31, 2022 1,276.13%
Dec 31, 2021 -611.53%
Sep 30, 2021 74.02%
Jun 30, 2021 7,615.41%
Mar 31, 2021 8,829.55%
Dec 31, 2020 10,695.04%
Sep 30, 2020 31.82%
Jun 30, 2020 97.34%
Mar 31, 2020 83.17%
Dec 31, 2019 60.48%
Sep 30, 2019 60.54%
Jun 30, 2019 58.87%
Mar 31, 2019 61.23%
Dec 31, 2018 330.29%
Sep 30, 2018 76.34%
Jun 30, 2018 81.43%
Mar 31, 2018 56.47%
Dec 31, 2017 83.98%
Sep 30, 2017 48.86%
Jun 30, 2017 60.02%
Mar 31, 2017 41.60%
Dec 31, 2016 59.35%
Sep 30, 2016 45.13%
Jun 30, 2016 44.95%
Mar 31, 2016 18.34%
Dec 31, 2015 18.83%
Sep 30, 2015 -33.80%
Jun 30, 2015 -73.30%
Mar 31, 2015 -154.68%
Dec 31, 2014 -218.76%
Sep 30, 2014 -2,129.23%
Jun 30, 2014 -6,805.57%
Mar 31, 2014 -8,679.87%
Dec 31, 2013 -3,389.61%
Sep 30, 2013 -11,321.69%
Jun 30, 2013 -2,755.60%
Mar 31, 2013 -2,826.02%
Dec 31, 2012 25.19%
Sep 30, 2012 -2,426.01%
Jun 30, 2012 -7,097.51%
Mar 31, 2012 67.24%
Dec 31, 2011 -690.17%
Sep 30, 2011 -476.22%
Jun 30, 2011 -392.00%
Mar 31, 2011 -358.03%